Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma.
OBJECTIVE
To investigate the roles of insulin-like growth factor II (IGF2), myeloperoxidase (MPO), E-cadherin (CDH1), urokinase and xeroderma pigmentosum group A and D (XPA, XPD) polymorphisms upon leiomyoma susceptibility.


METHODS
Women were divided into: group 1, leiomyoma (n=158); group 2, non-leiomyoma (n=156). Polymorphisms (IGF2 exon 9*A/G, MPO-463*A/G, CDH1-Pml I, urokinase-ApaL, XPA*A-23G, XPD*Lys751Gln) were amplified by polymerase chain reaction and detected by electrophoresis after restriction enzyme digestion. Genotype and allelic frequencies were compared between both groups.


RESULTS
Associations between leiomyoma with IGF2 and CDH1 polymorphism exist. Proportions of IGF2 exon 9*AA/AG/GG in and CDH1* CC/CT/TT in the groups were: group 1, 38/39.2/22.8% and 27.8/66.5/5.7%; group 2, 22.4/53.9/23.7% and 21.2/64.1/14.7. MPO, urokinase, XPA and XPD in both groups were non-significantly different. Proportions of MPO*AA/AG/GG, urokinase*CC/CT/TT, XPA*AA/AG/GG and XPD*AA/AC/CC were: group 1: 1.9/23.4/74.7%, 0.6/7/92.4%, 20.9/55.1/24%, 85.4/14.6/0%; group 2: 3.8/24.4/71.8%, 1.3/4.5/94.2%, 22.4/53.9/23.7%, 84.6/15.4/0%.


CONCLUSIONS
IGF2*A allele and CDH1*C allele were correlated with leiomyoma susceptibility, which may be associated with leiomyoma development. MPO, urokinase, XPA and XPD polymorphisms are not related to leiomyoma susceptibilities.
Hsieh
Yao-Yuan
YY
School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan, ROC.
Chang
Chi-Chen
CC
Wang
Yu-Kuo
YK
Hsu
Kung-Hao
KH
Chen
Chih-Ping
CP
Hsu
Chin-Mu
CM
Tsai
Fuu-Jen
FJ
D000328:Adult; D015820:Cadherins / Q000235:genetics*; D005091:Exons; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000235:genetics*; D007889:Leiomyoma / Q000209:etiology / Q000235:genetics*; D009195:Peroxidase / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics*; D014594:Uterine Neoplasms / Q000209:etiology / Q000235:genetics*; D051760:Xeroderma Pigmentosum Group A Protein / Q000235:genetics*; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
D015820:Cadherins; C497314:XPA protein, human; D051760:Xeroderma Pigmentosum Group A Protein; D007335:Insulin-Like Growth Factor II; D009195:Peroxidase; D014568:Urokinase-Type Plasminogen Activator; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human